Abiraterone and Prednisone or Darolutamide for the Treatment of Advanced Prostate Cancer
Phase 2
Recruiting
- Conditions
- Advanced Prostate AdenocarcinomaStage III Prostate Cancer AJCC v8Stage IV Prostate Cancer AJCC v8
- Interventions
- First Posted Date
- 2023-12-15
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Mamta Parikh
- Target Recruit Count
- 75
- Registration Number
- NCT06173362
- Locations
- 🇺🇸
University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
PLZ4-Coated Paclitaxel-Loaded Micelles for the Treatment of Patients With Recurrent or Refractory Non-Muscle Invasive Bladder Cancer
Phase 1
Recruiting
- Conditions
- Recurrent Non-Muscle Invasive Bladder CarcinomaStage 0is Bladder Cancer AJCC v8Stage 0a Bladder Cancer AJCC v8Stage I Bladder Cancer AJCC v8
- Interventions
- Drug: PLZ4-coated paclitaxel loaded micelles (PPM)
- First Posted Date
- 2023-12-15
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Mamta Parikh
- Target Recruit Count
- 12
- Registration Number
- NCT06173349
- Locations
- 🇺🇸
University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
Selinexor and Pembrolizumab for the Treatment of Cisplatin-Ineligible or Cisplatin-Refractory Locally Advanced or Metastatic Urothelial Carcinoma
Phase 1
Recruiting
- Conditions
- Refractory Urothelial CarcinomaLocally Advanced Urothelial CarcinomaAdvanced Urothelial CarcinomaMetastatic Urothelial Carcinoma
- Interventions
- Biological: Pembrolizumab
- First Posted Date
- 2021-04-23
- Last Posted Date
- 2023-07-03
- Lead Sponsor
- Mamta Parikh
- Target Recruit Count
- 12
- Registration Number
- NCT04856189
- Locations
- 🇺🇸
University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
Enzalutamide and Niclosamide in Treating Patients With Recurrent or Metastatic Castration-Resistant Prostate Cancer
Phase 1
Completed
- Conditions
- Stage IV Prostate CancerRecurrent Prostate CarcinomaMetastatic Prostate Carcinoma
- Interventions
- First Posted Date
- 2017-04-21
- Last Posted Date
- 2023-04-26
- Lead Sponsor
- Mamta Parikh
- Target Recruit Count
- 6
- Registration Number
- NCT03123978
- Locations
- 🇺🇸
University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
Enzalutamide and Indomethacin in Treating Patients With Recurrent or Metastatic Hormone-Resistant Prostate Cancer
Phase 1
Recruiting
- Conditions
- Metastatic Prostate CarcinomaRecurrent Prostate CarcinomaStage IV Prostate Cancer
- Interventions
- First Posted Date
- 2016-10-17
- Last Posted Date
- 2023-11-29
- Lead Sponsor
- Mamta Parikh
- Target Recruit Count
- 38
- Registration Number
- NCT02935205
- Locations
- 🇺🇸
University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
Abiraterone Acetate, Niclosamide, and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer
Phase 2
Active, not recruiting
- Conditions
- Recurrent Prostate CarcinomaStage IV Prostate CancerMetastatic Prostate Carcinoma
- Interventions
- First Posted Date
- 2016-06-21
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Mamta Parikh
- Target Recruit Count
- 37
- Registration Number
- NCT02807805
- Locations
- 🇺🇸
University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
© Copyright 2025. All Rights Reserved by MedPath